Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
ProPhotonix Director/PDMR Dealings and Equity
-
Verisk Analytics (VRSK) PT Raised to $108 at Cantor Fitzgerald Following Investor Day
-
bluebird bio (BLUE) PT Raised to $113 at Cantor Fitzgerald, 'Believes in the Science But Not the Valuation'
-
Revance Therapeutics (RVNC) Prices 5.34M Offering of Common Stock at $31/Share
-
Revance Announces Pricing of Public Offering of Common Stock
-
Cantor Fitzgerald Starts Exela Technologies (XELA) at Overweight
-
Cantor Fitzgerald Starts Strongbridge Biopharma (SBBP) at Overweight Noting Undervalued Shares
-
Omnicell (OMCL) PT Raised to $60 at Cantor Fitzgerald, 'New Product Announcements Improve Growth Outlook'
-
Heron Therapeutics (HRTX) Prices $150M Common Stock Offering
-
Heron Therapeutics Announces Pricing of Public Offering of Common Stock
-
ProPhotonix Announces Application for Block Admission
-
Heron Therapeutics (HRTX) Plans Public Offering of Common Stock
-
Heron Therapeutics Announces Public Offering of Common Stock
-
BGC Partners (BGCP) Announces Launch of Newmark Group (NMRK) IPO Roadshow
-
BGC Partners Announces Launch Of Newmark Group IPO Roadshow
-
Northern Trust Appoints Head of ETF Capital Markets for FlexShares
-
Freddie Mac Prices $637 Million Seniors Housing Multifamily K Certificates
-
McEwen Mining Announces Timmins Exploration Program and Funding
-
Cantor Fitzgerald Sees ~4.9M Shares of Teva (TEVA) Being Bought Amid TASE Index Rebalance
-
Euronext Expands Its Federal Model with the Acquisition of the Irish Stock Exchange
-
Cantor Fitzgerald Starts Xencor, Inc. (XNCR) at Overweight
-
Cantor Fitzgerald Reiterates Overweight on UnitedHealth Group (UNH)
-
Legacy Acquisition Corp. Class A Common Stock And Warrants To Commence Trading Separately On November 30, 2017
-
JVB Financial Announces New Hires
-
Corbus Pharmaceuticals Holdings, Inc. Announces Exercise of Option to Purchase Additional Shares in Public Offering
-
UPDATE: Cantor Fitzgerald Downgrades Cytokinetics (CYTK) to Neutral
-
Ardelyx, Inc (ARDX) PT Lowered to $12 at Cantor Fitzgerald
-
Legacy Acquisition Corp. Announces Closing of $300,000,000 Initial Public Offering
-
Cantor Fitzgerald Maintains Bullish View on Synergy Pharmaceuticals (SGYP) Into Jan 24 PDUFA
-
AxoGen Announces Closing of Public Offering of Common Stock
-
PayPal (PYPL) PT Raised to $85 at Cantor Fitzgerald; Reiterates Overweight
-
Luxoft Holding (LXFT): Results In Line with Expectations, PT To $52 - Cantor Fitzgerald
-
Cantor Fitzgerald Downgrades HMS Holdings (HMSY) to Neutral
-
Globant (GLOB): Revenue Outperformance But Earnings Just In Line - Cantor
-
Playlogic Entertainment, Inc. (LGC) Prices 30M Share IPO at $10/Sh
-
Legacy Acquisition Corp. Announces Pricing of $300,000,000 Initial Public Offering
-
Haymaker Acquisition Corp. Class A Common Stock and Warrants to Commence Trading Separately on November 17, 2017
-
Acorda Therapeutics, Inc. (ACOR) PT Lowered to $16 at Cantor Fitzgerald; Tozadenant Serious Adverse Events Announcement a 'Clear Setback'
-
AxoGen (AXGN) Prices Public Offering of Common Stock at $21/Share
-
AxoGen, Inc. Announces Pricing of Public Offering of Common Stock
-
AxoGen (AXGN) Announces 1M Share Common Offering
-
AxoGen, Inc. Announces Proposed Public Offering of Common Stock
-
LifeSci Advisors Continues Expansion of U.S. Team with Appointment of Jeremy Feffer
-
LifeSci Advisors Continues Expansion of U.S. Team with Appointment of Jeremy Feffer
-
Albireo Reports Third Quarter 2017 Financial Results
-
Prometic Reports 2017 Third Quarter Highlights and Financial Results
-
Amarin (AMRN): Additional Data Increases Confidence In Vascepa - Cantor Fitzgerald
-
RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares
-
RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares
-
RedHill Biopharma Reports 2017 Third Quarter Financial Results

